Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis

医学 多西紫杉醇 前列腺癌 荟萃分析 肿瘤科 雄激素剥夺疗法 内科学 随机对照试验 恩扎鲁胺 癌症 雄激素受体
作者
Soumyajit Roy,Gagan Fervaha,Daniel E. Spratt,Yilun Sun,Amar U. Kishan,Andrew Loblaw,Shawn Malone,Michael Ong,Fred Saad,Christopher J.D. Wallis,Scott C. Morgan
出处
期刊:European Urology [Elsevier BV]
卷期号:86 (1): 10-17 被引量:8
标识
DOI:10.1016/j.eururo.2024.03.018
摘要

The utility of prostate radiotherapy (RT) is unclear in men with metastatic hormone-sensitive prostate cancer (mHSPC) receiving intensified systemic therapy with androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs). We performed a network meta-analysis of randomized controlled trials (RCTs) to investigate the role of prostate RT in low-volume mHSPC. Bibliographic databases and conference proceedings were searched through July 2023 for RCTs evaluating the addition of ARPIs or prostate RT to standard of care (SOC) systemic therapy, defined as ADT or ADT plus docetaxel, for the initial treatment of mHSPC. We focused exclusively on aggregate data from the low-volume mHSPC subpopulation in these trials. We pooled the treatment arms into four groups: SOC, SOC plus ARPI, SOC plus RT, and SOC plus ARPI plus RT. The primary outcome was overall survival (OS). To compare treatment strategies, a fixed-effects Bayesian network meta-analysis was undertaken, while a Bayesian network meta-regression was performed to account for across-trial differences in docetaxel use as part of SOC and in proportions of patients with de novo presentation. Ten RCTs comprising 4423 patients were eligible. The Surface Under the Cumulative Ranking Curve scores were 0.0006, 0.45, 0.62, and 0.94 for SOC, SOC plus RT, SOC plus ARPI, and SOC plus ARPI plus RT, respectively. On a meta-regression, in a population with de novo mHSPC and no docetaxel use, we did not find sufficient evidence of a difference in OS between SOC plus ARPI plus RT versus SOC plus ARPI (hazard ratio [HR]: 0.76; 95% credible interval: 0.51–1.16) and SOC plus RT versus SOC plus ARPI (HR: 1.10; 95% credible interval: 0.92–1.42). There was some evidence that SOC plus ARPI plus RT reduced mortality compared with the next best strategy of SOC plus ARPI in patients with low-volume de novo mHSPC. A meta-analysis with individual patient data or an RCT is needed to confirm these findings.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
美丽的安珊完成签到,获得积分10
2秒前
2秒前
4秒前
Gilana完成签到,获得积分10
4秒前
xyh发布了新的文献求助10
4秒前
江璃完成签到,获得积分10
5秒前
TT发布了新的文献求助10
5秒前
美梦成真完成签到,获得积分10
6秒前
Gakay完成签到,获得积分10
6秒前
量子星尘发布了新的文献求助10
7秒前
szj完成签到,获得积分0
8秒前
旦皋完成签到,获得积分10
8秒前
赘婿应助花壳在逃野猪采纳,获得10
9秒前
卷卷完成签到,获得积分10
11秒前
JSY完成签到 ,获得积分20
11秒前
xyh完成签到,获得积分10
12秒前
小曾应助Florencia采纳,获得10
13秒前
神外王001完成签到 ,获得积分10
13秒前
18秒前
你是谁完成签到,获得积分10
19秒前
majf完成签到,获得积分10
20秒前
linhanwenzhou完成签到,获得积分10
20秒前
JSY关注了科研通微信公众号
20秒前
853225598完成签到,获得积分10
20秒前
798完成签到,获得积分10
21秒前
善学以致用应助董怼怼采纳,获得10
21秒前
妍儿完成签到,获得积分20
22秒前
隐形曼青应助高大的水壶采纳,获得10
22秒前
马哥二弟无敌完成签到 ,获得积分10
23秒前
24秒前
Florencia完成签到,获得积分10
24秒前
务实颜完成签到 ,获得积分10
24秒前
24秒前
amberzyc应助小远采纳,获得10
25秒前
25秒前
26秒前
26秒前
27秒前
27秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038368
求助须知:如何正确求助?哪些是违规求助? 3576068
关于积分的说明 11374313
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029